RaQualia Pharma Inc. Provided earnings guidance for the year ending December 31, 2021. For the period, the company expects net sales of ¥2,738 million, operating profit of ¥420 million and profit attributable to owners of the parent of ¥343 million or ¥16.41 earnings per share.